GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » EV-to-FCF

Ascelia Pharma AB (FRA:7ZA) EV-to-FCF : -4.09 (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ascelia Pharma AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ascelia Pharma AB's Enterprise Value is €21.72 Mil. Ascelia Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-5.32 Mil. Therefore, Ascelia Pharma AB's EV-to-FCF for today is -4.09.

The historical rank and industry rank for Ascelia Pharma AB's EV-to-FCF or its related term are showing as below:

FRA:7ZA' s EV-to-FCF Range Over the Past 10 Years
Min: -8.78   Med: 0   Max: 0
Current: -3.61

FRA:7ZA's EV-to-FCF is ranked worse than
100% of 385 companies
in the Biotechnology industry
Industry Median: 8.82 vs FRA:7ZA: -3.61

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), Ascelia Pharma AB's stock price is €0.26. Ascelia Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.110. Therefore, Ascelia Pharma AB's PE Ratio (TTM) for today is At Loss.


Ascelia Pharma AB EV-to-FCF Historical Data

The historical data trend for Ascelia Pharma AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB EV-to-FCF Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -7.92 -16.37 -6.39 -2.82 -0.73

Ascelia Pharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.73 -2.91 -3.82 -2.40

Competitive Comparison of Ascelia Pharma AB's EV-to-FCF

For the Biotechnology subindustry, Ascelia Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's EV-to-FCF falls into.



Ascelia Pharma AB EV-to-FCF Calculation

Ascelia Pharma AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=21.724/-5.315
=-4.09

Ascelia Pharma AB's current Enterprise Value is €21.72 Mil.
Ascelia Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascelia Pharma AB  (FRA:7ZA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Ascelia Pharma AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.26/-0.110
=At Loss

Ascelia Pharma AB's share price for today is €0.26.
Ascelia Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.110.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Ascelia Pharma AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines